728

Web Search

 

Jul 1, 2011

Yeast DNA and RNA Methods

Yeast DNA and RNA Methods

Beta-gal Assay

Bgal filter assay

Bgal liquid assay

Bgal plate overlay assay

Determination of replication Timing of yeast by Comparative Hybridization

Determination of replication Timing of yeast by Density Transfer

Determination of replication Timing of yeast by Transient Hemimethylation

DNA Replication Techniques

Isolation of yeast DNA by smash and grab method

Liquid Sporulation

Plasmid Rescue from Yeast from Liquid Culture and Clony Rescue

Preparation of Yeast DNA Embedded in Agarose Plugs

Quantitative Mating Assay

Rather Rapid Genomic Prep

RNA Prep

ß-GAL Filter Assay

ß-gal Lift method

Yeast Chromosomal DNA Preparation

Yeast DNA Miniprep Protocol (Haber Lab)

Yeast DNA Preparation by rapid glass bead method

Yeast Genomic DNA Extraction 2-D Gels

Yeast Genomic DNA Isoaltion

Yeast Genomic DNA Miniprepartion

Yeast protocol (for microarray)

Yeast quick plasmid DNA Preparation

Yeast RNA Minipreparation

Databases of Yeast Genetics

Yeast Genetics

EMS Mutagenesis

EMS mutagenesis of yeast

Generating a Temperature Sensitive Allele

Genome-wide Gene Expression Analysis

Pheromone halo assay (Dohlman Lab)
UV mutagenesis (Corbett Lab)
Replication timing by density transfer (Fangman / Brewer Lab)
beta-Gal reporter gene assay (Dohlman Lab)
beta-Gal filter assay (Dohlman Lab)
beta-Gal filter assay (Breeden Lab)
b-Gal filter assays (Herskowitz Lab)
EMS mutagenesis of yeast (Hahn Lab)
Replication timing by comparative hybridization (Fangman / Brewer Lab)
Replication timing using transient hemimethylation (Fangman / Brewer Lab)
X-Gal agarose overlay assay (Herskowitz Lab)
Procedure for generating ts alleles of NUT2 (Herskowitz Lab)
Yeast Genetics Protocols (Herskowitz Lab)

Yale Genome Analysis Center

Two-Hybrid System

Brent Lab Two-Hybrid Information

Development of an optimized interaction-mating protocol for large-scale two-hybrid analyses.

GST fusion protein purification from Yeast (Dohlman Lab)

Handling and using insertion libraries

Nature Protocols: Smart-pool-array protocol for a yeast two-hybrid assay.

Performing a hunt by interaction mating (Finely Lab)
The yeast two-hybrid system for beginners (Newman / Collinge Lab)
Two-hybrid system (Millner Lab)
Two-hybrid analysis of genetic regulatory networks (Finely Lab)
Two-hybrid system (Finely Lab)
Two-hybrid system (Gietz Lab)

Two Hybrid System Transformation

Yeast Two-Hybrid : State of the Art (Van Criekinge, Beyaert)

Dec 4, 2010

US Scientists Reverse Signs of Aging in Mice

Elderly mice restored to middle age

Harvard scientists say they were able to reverse signs of aging in mice by tweaking a gene which protects cells from the harmful, cumulative effects associated with growing old.

Harvard scientists say they were able to reverse signs of aging in mice by tweaking a gene which protects cells from the harmful, cumulative effects associated with growing old.

Scientists say they have reversed age-related degeneration in mice, resulting in an improvement in the rodents' fertility and the growth of new brain tissue. But it could be some time before the technique might be used in humans.

Fountain of youth

Scientists at Harvard University's Dana-Farber Cancer Institute in Boston report they were able to reverse signs of aging in mice by tweaking a gene that protects cells from the harmful, cumulative effects associated with growing old.

The gene is involved in the production of structures at the tips of DNA chromosomes called telomeres.

Telomeres are like the plastic caps on the ends of shoe laces that keep them from becoming frayed. In the case of chromosomes, the telomeres protect the strands of DNA from environmental assaults such as chemical and radiation exposure.

But every time a cell divides, its telemeres shorten, eventually leading to DNA damage and aging.

In studies with mice, researchers switched off the telomerase gene and watched the rodents rapidly develop age-related impairments.

Eternally young?

However, when they turned the genes back on on, the animals' declines reversed.

"Their fertility was restored. We also saw a big effect on the lining of the intestines and as well as in the brain, which was a little bit unexpected," says lead researcher Mariela Jaskelioff. "We actually saw a decrease in the size of the brains of these mice with premature aging. And we could reverse these by reactivating telomerase."

The mice in the study were at an age equivalent of an 80- or 90-year-old human. Researchers restored them to middle age by turning on the telomerase gene.

Despite the encouraging results, the genetic manipulation is not the secret to eternal youth for humans. Jaskelioff says the telomerase gene is involved in the growth of both normal and cancerous cells.

"The fear is that in humans, adult humans, we accumulate mutations all through our lifetimes," she says. "And if we were to reactivate telomerase in cells that have malignant mutations, then the propensity to develop cancer would probably be exacerbated."

However, according to Jaskelioff, it might be possible to stimulate the telomerase gene for short periods of time in people with a rare disorder which causes premature aging.

Scientists describe how they reversed aging in mice in an article published in the journal Nature Medicine.

Nov 29, 2010

Gene therapy 'memory boost hope'


This research adds a piece to the Alzheimer's puzzle and provides new leads for researchers”

Rebecca Wood

Alzheimer's Research Trust

A gene therapy technique which aims to ease memory problems linked to Alzheimer's Disease has been successfully tested in mice.

US scientists used it to increase levels of a chemical which helps brain cells signal to each other.

This signalling is hindered in Alzheimer's Disease, the journal Nature reported.

The Alzheimer's Research Trust said the study suggested a way to keep nerve cells in the brain communicating,

Ageing populations in many countries around the world mean that Alzheimer's disease and other forms of dementia are set to increase.

Researchers at the Gladstone Institute of Neurological Disease in San Francisco believe that boosting the brain chemical, a neurotransmitter called EphB2, could help reduce or even prevent some of the worst effects of the condition.

Their research suggests that the chemical plays an important role in memory, and is depleted in Alzheimer's patients.

One of the most noticeable features about the brains of Alzheimer's patients is the build-up of "plaques" of a toxic protein called amyloid. Over time this leads to the death of brain cells.

'Thrilled'

However, another characteristic of amyloid is its apparent ability to bind directly to EphB2, reducing the amount available to brain cells, which could in part explain the memory symptoms involved.

To test this idea, they used gene therapy experiments to artificially reduce and increase the amount of available EphB2 in the brains of mice.

When levels of the chemical were reduced, healthy mice developed memory symptoms similar to those seen in mice bred to have a condition similar to Alzheimer's.

Conversely, when the "Alzheimer's" mice were given gene therapy which boosted levels of EphB2, their memory symptoms disappeared.

Dr Lennart Mucke, who led the study, said that his team had been "thrilled" to find this.

"We think that blocking amyloid proteins from binding to EphB2, and enhancing EphB2 levels or functions with drugs might be of benefit in Alzheimer's Disease."

However UK researchers said that the find, while interesting, did not offer a swift answer to Alzheimer's patients.

Rebecca Wood, chief executive of the Alzheimer's Research Trust, said: "Our brains are hugely complex and understanding how they work and become damaged by diseases like Alzheimer's is a massive task.

"This research adds a piece to the Alzheimer's puzzle and provides new leads for researchers.

"It suggests a way to keep nerve cells in the brain communicating, which is vital for thinking and memory."

But she added: "We don't know yet if these findings will lead to a new treatment for Alzheimer's - that's some way off."

(BBC)

Nov 25, 2010

New Era for Human Genetics Begins

1000 Genomes Project focuses on genetic differences which could lead to greater understanding of disease, evolution

An international effort to build a detailed map of human genetic variation has completed its pilot phase and could shape a new understanding of human evolution and may help in fighting disease.

The 1000 Genomes Project aims to sequence the genetic code of 2,500 people.
The 1000 Genomes Project aims to sequence the genetic code of 2,500 people.

A decade ago, scientists made worldwide headlines when they announced they had sequenced the human genome - made a kind of map, in other words, of DNA, the inherited molecule that makes us human. But that was only one genome. Everyone on Earth has a unique genetic makeup, and researchers have now sequenced thousands of individuals' DNA.

The first effort to sequence the human genome came in under budget and ahead of schedule, and the process has gotten progressively cheaper and faster.

"In the last 10 years," said Richard Durbin, co-chair of the 1000 Genomes Project. "DNA sequencing technology has advanced dramatically so it has become feasible to systematically sequence many people to find genetic variants, and build a catalog which we can use as a basis for investigations into disease, genetics, and which variants may be functional."

DNA Strand
Getty Images/iStockphoto

Genetic variations are the way your genes differ from other people's. Some variations relate to differences we can see, like eye color. Others may put us at greater risk for disease. Some variations are inherited. Others can be caused by toxic chemicals or radiation or simply by mistakes in copying DNA.

Most genetic variations are found in lots of unrelated people. Scientists have started to investigate possible links between disease and some of these variations, called single nucleotide polymorphisms, or SNPs. The researchers aim to probe deeper.

"The 1000 Genomes Project makes this approach much more complete and much more powerful," said David Altschuler, 1000 Genomes co-chair, "by going down to much lower frequencies, and also broader range of populations and more complete data in each frequency range and each population."

At the University of Washington in Seattle, meanwhile, Evan Eichler and his colleagues have been using a technique to identify pieces of the genome that duplicate other parts of the DNA code. Writing in the journal Science, the researchers describe how they identified more than four million places where they found these duplicates, called copy-number variants.

Eichler says these variants could help identify genes that may be associated with disease that are what he called "inaccessible" using other techniques. He also said it can help improve the understanding of human evolution.

"We think the veil has been lifted for us in terms of a whole new level of genetic diversity. And when we compare these roughly 159 humans that we've analyzed to date, and compared variations they've found in their genomes to that of the great apes, we have the ability, I think pretty clearly, to identify the genes and the gene families which have expanded specifically in our lineage of evolution since we separated from that of chimpanzee and gorilla," Eichler said.

Back at the 1000 Genomes project, co-chair David Altshuler says the organization's work will provide data so scientists can answer questions about the role genes play in health based on facts, not guesswork. "And so rather than speculate," he said, "I think we'd say we are helping to create the foundation to answer that question, and anyone who does speculate, I think is speculating."

By the way, the goal of the 1000 Genomes project isn't to sequence the genetic code of exactly 1,000 people. Instead, the aim is to identify genetic variations that occur in at least one out of every 100 people or one percent. In particular, that will require using genetic material from many thousands of people from all over the world. And it will need to include a lot more geographic diversity. Only a handful of genomes from Latin America and Africa have been sequenced so far.

Researchers May Some Day Treat Depression with Gene Therapy

Jessica Berman 21 October 2010

Doctors may some day treat patients suffering from major depression with gene therapy. So say scientists who report they are encouraged by human and animal research.

Scientists have identified a protein called p11 in a small region of the brain that plays a role in major depression. The brain region, known as the nucleus accumbens, is responsible for feelings of pleasure and reward.

Researcher Michael Kaplitt of the department of neurological surgery at Presbyterian / Weill Cornell Medical Center in New York, says mice bred without the p11 gene showed signs of severe depression, including passivity when dangled by their tails instead of trying to get away and a disinterest in sugar water, which he says is like candy to mice who normally drink a lot of it.

Kaplitt also says autopsy studies of tissue taken from the brains of people with severe depression showed extremely low levels of p11 in the nucleus accumbens compared to the brains of individuals without depression.

"So if human beings have lower levels of p11 in this area of the brain, if they have depression, and if animals when they have low p11 levels in this area show depression-like behaviors, then that suggests that this might be a very important component of depression; not the only component but it may be a very important component," said Kaplitt.

Using so-called knock-out mice that completely lacked the p11, Kaplitt says researchers inserted a normal copy of the protein into a harmless virus and infused it into the nucleus accumbens of the depressed rodents.

"Now when we restored it to these adult mice, it completely normalized their behaviors; it reversed these depression-like behaviors so that they were back to normal," he said. "So that suggested that if you have low p11 levels in that area, and if that is a cause of depression, that we could potentially reverse it with gene therapy."

Kaplitt and colleagues have also been conducting promising therapy trials with Parkinson's disease patients.

The researchers hope to soon begin gene therapy experiments in patients with major depression who do not respond to anti-depressant medications.

An article on gene therapy for major depression is published in the journal Science Translational Medicine.